Sign up to save your podcasts
Or
Share Managing Toxicities of TKIs and HIF-2 inhibitor in Renal Cell Carcinoma (RCC)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Managing Toxicities of TKIs and HIF-2 inhibitor in Renal Cell Carcinoma (RCC)
Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by world-renowned medical oncologist Dr. Monty Pal from the City of Hope. Together, they dived deep into the management of side effects associated with tyrosine kinase inhibitors (TKIs) and HIF-2 alpha inhibitors used in treating renal cell carcinoma (RCC).
Episode Highlights:
• Understanding TKIs and HIF-2 Inhibitors: A discussion on the available oral treatment options for RCC, including cabozantinib, lenvatinib, and axitinib.
• Dosing Strategies: Insights on starting doses, titration, and the importance of managing side effects without compromising quality of life.
• Common Side Effects: hypertension, diarrhea, fatigue, and how they relate to the class effect of these medications.
• Clinical Pearls: Dr. Pal shared valuable tips on managing toxicities, including the use of treatment breaks and supportive care strategies.
• Second-Line Treatments: A look at tivozanib and belzutifan, including their unique side effects and management strategies.
Join us as we emphasized the importance of maintaining quality of life for patients undergoing treatment for metastatic RCC.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to check out our other episodes for more insights on treatment algorithms, conference highlights, and challenging cases from the community.
View all episodes
By Oncology Brothers
4.8
3939 ratings
Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by world-renowned medical oncologist Dr. Monty Pal from the City of Hope. Together, they dived deep into the management of side effects associated with tyrosine kinase inhibitors (TKIs) and HIF-2 alpha inhibitors used in treating renal cell carcinoma (RCC).
Episode Highlights:
• Understanding TKIs and HIF-2 Inhibitors: A discussion on the available oral treatment options for RCC, including cabozantinib, lenvatinib, and axitinib.
• Dosing Strategies: Insights on starting doses, titration, and the importance of managing side effects without compromising quality of life.
• Common Side Effects: hypertension, diarrhea, fatigue, and how they relate to the class effect of these medications.
• Clinical Pearls: Dr. Pal shared valuable tips on managing toxicities, including the use of treatment breaks and supportive care strategies.
• Second-Line Treatments: A look at tivozanib and belzutifan, including their unique side effects and management strategies.
Join us as we emphasized the importance of maintaining quality of life for patients undergoing treatment for metastatic RCC.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to check out our other episodes for more insights on treatment algorithms, conference highlights, and challenging cases from the community.
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
320 Listeners
Journal of Clinical Oncology (JCO) Podcast
42 Listeners
Research To Practice | Oncology Videos
111 Listeners
JAMA Clinical Reviews
501 Listeners
ASCO Daily News
60 Listeners
Core IM | Internal Medicine Podcast
1,110 Listeners
OncoPharm
182 Listeners
ASCO Guidelines
46 Listeners
OncLive® On Air
22 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
350 Listeners
Lung Cancer Considered
27 Listeners
The Passive Income MD Podcast
277 Listeners
Oncology Today with Dr Neil Love
60 Listeners
Two Onc Docs
181 Listeners
Blood Cancer Talks
48 Listeners